Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COVID-19 vaccine + hepatitis A vaccine + diphtheria + pertussis + tetanus vaccine
- Development stage
- Unknown
- Lead developer
- Oregon Health and Science University
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This entry refers to a specific co-administration regimen consisting of a COVID-19 booster vaccine, a Hepatitis A (HepA) vaccine, and a Tetanus, Diphtheria, and acellular Pertussis (Tdap) booster vaccine. This combination is being evaluated by Oregon Health and Science University (OHSU) in the Phase 4 COVER-CoAd clinical trial (NCT05065879). The study aims to assess the safety and immunogenicity of giving these three vaccines concurrently, particularly in patients with rheumatic diseases and other chronic conditions who are receiving immunomodulatory therapies. The primary objective is to determine if co-administration affects the immune response to the COVID-19 booster compared to separate administration, addressing a critical need for efficient vaccination schedules in immunocompromised populations.
- Other names
- COVID-19 booster + HepA + Tdap co-administrationCOVID-19 vaccine + hepatitis A vaccine + Tdap vaccine
02
Targets
FHA (Filamentous hemagglutinin)T1F (Type 1 fimbriae)SARS-CoV-2 spikePRN (Pertactin)Diphtheria toxin
Beyond the preview
Go deeper on COVID-19 vaccine + hepatitis A vaccine + diphtheria + pertussis + tetanus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COVID-19 vaccine + hepatitis A vaccine + diphtheria + pertussis + tetanus vaccine.